加州大学圣迭戈分校的研究团队在一项随机对照临床试验中发现，GLP-1药物司美格鲁肽具有减缓生物衰老的潜力。1该试验招募了108名患有HIV相关脂肪营养不良症的成人，其中约半数接受每周司美格鲁肽注射，另一半接受安慰剂，治疗周期为32周。1
研究利用表观遗传学时钟测量DNA甲基化变化，通过DunedinPACE工具进行评估。1结果表明司美格鲁肽使生物衰老速度减缓9%，并显著降低与全因死亡率和年龄相关疾病相关的生物过程。1在另一项为期24周的试验中，42%的HIV和脂肪肝患者的生物衰老速度出现减缓，34%患者的全因死亡率相关衰老指标改善，近49%患者的端粒长度增加。1
研究人员认为司美格鲁肽通过减少炎症、代谢应激和内脏脂肪积累来发挥作用。1该研究由加州大学圣迭戈分校Stein衰老研究所等机构合作完成，已发表在《自然通讯》杂志上，并获得美国国立卫生研究院和James B. Pendleton慈善信托基金的资助。1
Researchers at the University of California, San Diego have found that semaglutide, a GLP-1 medication, may slow the accumulation of biological aging markers in humans. 1 In a randomized controlled clinical trial involving 108 adults with HIV-associated lipodystrophy, approximately half of the participants received weekly semaglutide injections while the other half received a placebo over a 32-week treatment period. 1 Using epigenetic clocks that measure DNA methylation changes, the research team discovered that semaglutide reduced the pace of biological aging by 9 percent, as measured by the DunedinPACE epigenetic clock. 1 The findings have been published in Nature Communications. 1
In a secondary study spanning 24 weeks with HIV and fatty liver disease patients, 42 percent showed slowed biological aging rates, 34 percent demonstrated reduced aging related to all-cause mortality risk, and nearly 49 percent exhibited increased telomere length. 1 The drug's anti-aging effects appear to work through reducing inflammation, metabolic stress, and visceral fat accumulation. 1 The research was conducted by the Stein Institute for Research on Aging at UC San Diego and collaborating institutions, with funding provided by the National Institutes of Health and the James B. Pendleton Charitable Trust. 1
评论
还没有评论，欢迎留下第一条。